Citi lowered the firm’s price target on Agilon Health (AGL) to 75c from 85c and keeps a Neutral rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Hold Rating on Agilon: Margin Improvement Efforts Tempered by Persistent Profitability and Cost Pressures
- Agilon Health price target lowered to 50c from $1 at Barclays
- Agilon Health Reports 2025 Losses, Outlines 2026 Turnaround
- Agilon Health reports Q4 EPS (46c), consensus (27c)
- Agilon Health sees FY26 revenue $5.41B-$5.58B, consensus $5.96B